PMV Pharmaceuticals, Inc.
NASDAQ:PMVPBiotechnology
+$0.04 today
- Market cap
- $65.06M
- Beta
- 1.36
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$1.47
Volume 0.43M
Average 0.38M
PMVP EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
PMV Pharmaceuticals, Inc.NASDAQ: PMVP
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$18M, compared with -$19.6M a year earlier. Trailing-twelve-month EBITDA was -$78.19M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -8.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18M-0.1% QoQ
- Last fiscal yearDec 2025
- -$79.78M-8.3% YoY
- LTMMar 2026
- -$78.19M+0.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +8.1% | +100.0% | +91.9 pp |
| 1 year | -8.3% | +100.0% | +108.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (79.78M) USD
- Year-over-year change
- -8.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (79.78M) | -8.3% |
| FY2024 | 2024-12-31 | (73.67M) | -8.8% |
| FY2023 | 2023-12-31 | (67.7M) | +6.8% |
| FY2022 | 2022-12-31 | (72.68M) | -28.5% |
| FY2021 | 2021-12-31 | (56.54M) | — |
EBITDA vs competitors
How PMVP compares with its peers on the latest reported figures
- PMVP's LTM Mar 2026 EBITDA of -$78.19M is the 6th highest of the 9 companies compared; the peer median is -$65.5M.
- Its year-over-year change of +0.2% is the 6th highest of 9, against a peer median of +2.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.3M | +203.4% | — | 18.5% | |
| LTM Mar 2026 | -$46.12M | +63.6% | — | — | |
| LTM Mar 2026 | -$58.88M | -297.6% | — | — | |
CBUSCibus, Inc. | LTM Mar 2026 | -$62.31M | +76.4% | — | 1453.8% |
| LTM Mar 2026 | -$68.69M | -10.6% | — | 36154.2% | |
| LTM Mar 2026 | -$78.19M | +0.2% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.08M | +0.7% | — | — |
| LTM Mar 2026 | -$104.13M | -8.2% | — | — | |
| LTM Mar 2026 | -$118.65M | +4.8% | — | 1298.7% | |
| Peer median (excluding PMVP) | -$65.5M | +2.7% | — | 1376.3% | |
Competitors are the stored peer set for PMVP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.28M | 650K | 1.26M | 1.14M | 0 |
| Gross Profit | (1.28M) | (650K) | (1.26M) | (1.14M) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 36.19M | 51.67M | 54.63M | 57.38M | 69.88M |
| Selling, General & Admin | 20.83M | 24.72M | 24.25M | 26.92M | 16.33M |
| Operating Expenses | 57.01M | 76.39M | 78.88M | 84.3M | 86.21M |
| Depreciation & Amortization | 1.28M | 650K | 1.26M | 1.14M | 133K |
| EBITDA | (56.54M) | (72.68M) | (67.7M) | (73.67M) | (79.78M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (58.29M) | (77.04M) | (80.13M) | (85.45M) | (86.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 449K | 3.63M | 11.17M | 10.66M | 6.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 470K | 3.71M | 11.17M | 10.64M | 6.29M |
| Income Before Tax | (57.82M) | (73.33M) | (68.96M) | (74.81M) | (79.91M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 23K | (9K) | 2K | (16.1M) | (2.17M) |
| Net Income | (57.85M) | (73.32M) | (68.96M) | (58.71M) | (77.74M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.28) | (1.61) | (1.44) | (1.14) | (1.48) |
| EPS (Diluted) | (1.28) | (1.61) | (1.44) | (1.14) | (1.48) |
| Weighted Avg Shares | 45.14M | 45.59M | 48.01M | 51.58M | 52.54M |
| Weighted Avg Shares (Diluted) | 45.14M | 45.59M | 48.01M | 51.58M | 52.54M |
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
Intrinsic Alpha fair value
Locked
Current Price
$1.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.